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Novel variation at chr11p13 associated with cystic fibrosis lung
disease severity
Hong Dang1, Paul J Gallins2, Rhonda G Pace1, Xue-liang Guo1, Jaclyn R Stonebraker1, Harriet Corvol3,4, Garry R Cutting5,6,
Mitchell L Drumm7, Lisa J Strug8,9, Michael R Knowles1 and Wanda K O’Neal1
Published genome-wide association studies (GWASs) identified an intergenic region with regulatory features on chr11p13
associated with cystic fibrosis (CF) lung disease severity. Targeted resequencing in n= 377, followed by imputation to n= 6,365
CF subjects, was used to identify unrecognized genetic variants (including indels and microsatellite repeats) associated with
phenotype. Highly significant associations were in strong linkage disequilibrium and were seen only in Phe508del homozygous
CF subjects, indicating a CFTR genotype-specific mechanism.
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Lung disease in cystic fibrosis (CF) varies even among patients
homozygous for the same genetic mutation (Phe508del), account-
ing for ~ 70% of CF alleles in Caucasian populations.1 Using
genome-wide association studies (GWASs) of 6,365 subjects, the
International Cystic Fibrosis Gene Modifier Consortium (abbre-
viated Consortium) has identified genetic loci associated with CF
lung disease severity, including an intergenic region on
chr11p13.2,3 The region is flanked by genes of high potential
relevance to CF lung disease, including: EHF, a transcription factor
involved in epithelial differentiation;4,5 and APIP, a dual-function
protein with roles in apoptosis and methionine salvage.6,7 The
gene PDHX is also in the region and shares a promoter with APIP.
Interestingly, the association signal in this region was stronger in
4,139 subjects homozygous for the most common CF mutation
(Phe508del) compared with an analysis that included CF
individuals with any severe CFTR genotype.2
Targeted resequencing is a viable approach to obtain a detailed
genetic variant map to facilitate post-GWAS mechanistic studies.
Toward this end, targeted resequencing (termed “ReSeqChr11”)
between the 5′ end of EHF and the 3′ end of PDHX (human
reference genome assembly (hg19), chr11:34,641,749–35,017,674)
was conducted using National Heart, Lung, and Blood Institute
(NHLBI) Resequencing and Genotyping Services (rsng.nhlbi.nih.
gov) (Figures 1a–c and Supplementary Figure 1). Resequencing
was conducted in 377 homozygous Phe508del subjects selected
from the larger Genetic Modifier Study cohort (University of North
Carolina at Chapel Hill/Case Western Reserve University) that was
recruited based on extremes of lung disease severity.8 Samples
selected were balanced for gender, lung disease severity
(KNoRMA; equal numbers 40.4 and o0.4),9 and by the
genotypes of the first reported3 single-nucleotide polymorphism
(SNP) with lowest P value, rs12793173, that was found to be in
strong linkage disequilibrium (LD) with the GWAS1+22 top SNP,
rs10742326 (Supplementary Table 1 and Supplementary Figures 1
and 2).2,3 All library preparation, enrichment, and sequencing were
performed at University of Washington Genome Center at Seattle
using a custom NimbleGen SeqCap probe library. Resequencing
provided coverage of ~ 81% of the entire region with an average
of 259 × coverage in the sequenced regions. Gaps in coverage
were because of highly repetitive features not compatible with the
NimbleGen capture platform (Figure 1c).
The paired-end 49 bp sequence reads were mapped to reference
genome hg19 by BWA v0.5.9-r16.10 SNP and insertion/deletion
(indel) calls were made at the University of Washington using an
automated software pipeline based on GATK toolkits v1.0-6125.11,12
The initial resequencing variant calls contained 4,800 variants,
including SNPs/indels, with National Center for Biotechnology
Information (NCBI) dbSNP134 annotation. Results for 94 previously
genotyped SNPs were 99.98% concordant. SNP/indel calls were
manually reviewed using both quality information from the variant
call format (VCF) files and selected spot checks of sequencing read
alignment from the binary alignment map (BAM) files, using the
Integrative Genomics Viewer (IGV) genome browser.13 When
reviewed by manual inspection in Integrative Genomics Viewer,
only 40% of indels called by the GATK toolkit were verified as
expected.14 The final, manually reviewed, SNP/indel calls from the
377 patient samples contained 2,991 variant calls over the
resequenced region. In addition, 101 polymorphic microsatellites
were called using GenoTan v0.1.5.15 We also identified a 113-bp
deletion, corresponding to rs78669256 (115 bp deletion on hg19;
0.34 minor allele frequency (MAF) in our resequenced samples), that
is part of a LINE element whose allele frequency and validation was
unknown from single-nucleotide polymorphism database (dbSNP;
Supplementary Figure 3).
The 2,991 variants were updated with NCBI dbSNP141
annotation through chromosomal location on hg19 (using
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Figure 1. Summary of ReSeqChr11 and cystic fibrosis (CF) lung disease association testing. Annotation information and CF lung disease
association test results were converted into either BED, or BEDGRAPH format with hg19 coordinates, and displayed as custom tracks on
University of California Santa Cruz (UCSC) genome browser with other relevant public annotations. The sections are: (a) scale bar and genome
coordinates on chr11 of UCSC hg19 reference genome; (b) UCSC genes annotation showing EHF, APIP, and PDHX genomic structure; (c) tiled
region of NimbleGen probes used to enrich the local genomic DNA to be resequenced; (d) CF lung disease severity association P values for
imputed single-nucleotide polymorphisms (SNPs)/indels among Phe508del homozygous patients; (e) CF lung disease severity association
P values in non-Phe508del homozygous patients; (f) CF lung disease severity association P values for microsatellite length polymorphisms in
Phe508del homozygous patients; (g) Scale bar and genome coordinates on chr11 of UCSC hg19 reference genome for zoom-in region;
(h) zoom-in view of genomic locations of SNPs/indels with most significant CF lung disease severity association (P value o10− 7), red bar
denoted with red asterisk (*) represents the top GWAS1+2 association SNP rs107423262 and blue asterisk (*) two SNPs down denotes top SNP
in this study (rs374869483); (i) genomic locations of all SNP/indels in the region with minor allele frequency (MAF) 40.05 colored by linkage
disequilibrium (LD) R2 values (R240.8, red lines; R2= 0.6–0.8, blue lines) compared with rs10742326; (j) DNase I hypersensitivity peak
assignments from pHTE cells; (k) DNase I hypersensitivity peak assignments from K562 leukemia cell line; and (l) summary of transcription
factor binding motifs from ENCODE chromatin immunoprecipitation sequencing (ChIP-seq) track.
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ANNOVAR16 and University of California Santa Cruz (UCSC)
genome databases), and 946 of them represent novel variants
that tended to be rare (Supplementary Figure 4, black dots), with
only 1 deletion (rs535729750 in dbSNP142) with MAF 40.1 and
only 23 deletions with MAF 40.01.
For association with CF lung disease severity, imputation to the
remainder (n= 6,365) of the Consortium patient cohort2 was
performed using MACH and Minimac2, as previously described,17
except that reviewed variants from ReSeqChr11 were used as the
reference set instead of 1000 Genomes variants. For microsatellite
repeat polymorphisms, imputation was performed using Beagle
v4.018 because of its ability to impute multiple alleles at a single
locus. Of the total 3,160 imputed variants over the resequenced
region, 1,485 were of sufficient MAF (40.01) and imputation
quality (R240.3, Supplementary Figure 4, vertical purple dashed
line) to provide reliable tests of association with CF lung disease
severity. Association testing was performed as previously
described2 with genotype PCs and sex as covariates. Briefly, the
Consortium’s quantitative lung phenotype9 was regressed on
imputed allele dosages using linear regression for each Con-
sortium cohort,2 followed by a meta-analysis to obtain the final
reported random effect P value. Microsatellite repeat variants were
coded using the most common allele as the reference, and all
other alleles as the alternative alleles before association testing.
Overall, the association P values are highly significant and
reflect published GWAS results2,3 (Table 1, Figure 1, and
Supplementary Figure 5). The top associated SNPs (Po10− 7) for
Phe508del homozygous subjects (n= 4,139) were located between
chr11:34,776,532 and 34,819,022, with the top SNP identified as
rs374869483 (Figure 1d and blue asterisk Figure 1h), an indel
located 580 bp downstream from the published top SNP
(rs10742326)2 (red asterisk, Figure 1h). Importantly, no significant
association findings (Po10− 5) were identified when the CF
cohort was limited to non-Phe508del homozygous subjects
(n= 2,226) (Table 1 and Figure 1e), and interaction analysis
between the top SNP (rs374869483) and Phe508del homozygous
status was significant at P= 0.046. This is consistent with previous
results that reported a reduction in significance of the associations
for this region in the entire CF cohort compared with Phe508del
homozygous subjects2 (Figure 1d). To evaluate association signals
independent of the SNP with lowest P value, the imputed dosage
of the conditioning SNP (rs10742326; top SNP in GWAS1+2 that is
in LD with rs374869483 (R2 = 0.987, D′= 0.995)) was included in
the statistical model as a covariate (Supplementary Figure 6). No
independent evidence of association was identified. In addition,
SNP-set Kernel Association Test (SKAT) and Burden tests19 applied
to the rare variants (MAF o0.01) in EHF, APIP, PDHX, and several
regulatory features from the 377 selected samples did not identify
any significant associations (Supplementary Table 2). This analysis
was limited to these subjects because rare variants cannot be
imputed to the entire population.
Together, the analysis suggests that the causal mechanism is
driven by one or more common variants in strong LD (Figure 2).
Indeed Haploview software (default settings)20 identified strong
LD among all highly associated variants (Figures 1g–i and 2a–d).
The top 5 haplotypes containing the 111 highly associated
SNPs are shown in Figure 2e, with 3 most common haplotypes
representing 38, 24, and 22% of all haplotypes. The fact
that variants associated with disease are often in high LD and
occur in context of local haplotype structure raised the
possibility that the mechanism of regulation acts through
multiple sites.
The intergenic nature of this region suggests it acts through
complex gene regulatory functions. Regulatory features down-
loaded from SeattleSeq Annotation 138, UCSC genome browser,
ENCODE (http://www.genome.gov/10005107),21–25 and Roadmap
Epigenomics servers, and annotation information over the
resequenced region on chr11, were collated by chromosomal
locations on hg19 (Supplementary Table 3).26 Careful
examination reveals complex, multiple, cell-type-specific
regulatory features; for example, DNase I hypersensitive sites
have been documented from human tracheal epithelium27 that
are distinct from those identified in K562 cells (Figure 1j vs. k). The
two DNase I hypersensitive sites in human tracheal epithelium
(11.2524 and 11.2525)27 contain a large number of transcription
factor binding sites (including four FOXA1 binding sites), as
identified in chromatin immunoprecipitation sequencing assays
(Figure 1l and Supplementary Table 4). In addition, epigenetic
markers found in Calu3 cell line (goblet cell model from human
lung adenocarcinoma) point to potential transcription enhancer
activity overlapping the two FOXA1 binding segments
(Supplementary Table 3). These features are potentially relevant
given the known roles for FOXA1 in mucin production.28,29
Furthermore, the highly significant SNP rs10742325 (Table 1) has
been found to show an allele-specific DNase I footprint (false
discovery rate o0.05).26
Table 1. Variants associated with CF lung disease severity with nominally more significant Phe508del homozygous P values than GWAS1+22 top SNP
(rs10742326)




β P value β P value
34810590 rs374869483a 0.992 TG T 0.415 − 0.117 1.81E− 10 − 0.045 6.79E− 02
34810443 rs10836312 0.997 T C 0.416 − 0.116 2.42E− 10 − 0.045 7.10E− 02
34808690 rs35532516a 0.996 GA G 0.416 − 0.116 2.42E− 10 − 0.045 6.94E− 02
34808486 rs1588354 0.996 T A 0.416 − 0.116 2.43E− 10 − 0.045 6.93E− 02
34809626 rs10742325 0.996 T G 0.416 − 0.115 2.44E− 10 − 0.045 7.08E− 02
34808920 rs10836310 0.983 T C 0.416 − 0.115 2.92E− 10 − 0.044 7.63E− 02
34809166 rs10836311 0.983 G A 0.416 − 0.115 2.92E− 10 − 0.044 7.64E− 02
34803694 rs11032868 0.974 G T 0.415 − 0.116 3.22E− 10 − 0.046 6.69E− 02
34810010 rs10742326 0.981 G A 0.416 −0.115 3.47E−10 −0.044 7.58E−02
Bold type highlights SNP of greatest significance from GWAS1+2.
Abbreviations: Alt, alternate allele; β, beta coefficient; CF, cystic fibrosis; dbSNP, database of single nucleotide polymorphisms (SNPs) and multiple small-scale
variations that include insertions/deletions, microsatellites, and non-polymorphic variants; GWAS, genome-wide association study; MAF, minor allele
frequency; SNP single-nucleotide polymorphism; Ref, reference allele.
aVariants not in GWAS1+2 analysis.
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Although our catalog of observed variants is still incomplete
because of gaps in sequence coverage and present limitations
of alignment and variant calling from short sequence reads,
these results suggest that there is no obvious single sequence
variant that is driving the association in the region. The
mechanism ultimately must explain how the regulatory features
operate in the context of cell-specific effects and explain the
Phe508del homozygous-specific association observed in this
region.
HGV DATABASE
The relevant data from this Data Report are hosted at the Human
Genome Variation Database at http://dx.doi.org/10.6084/m9.fig-
share.hgv.838 and http://dx.doi.org/10.6084/m9.figshare.hgv.841.
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